Re: reposted: Biaxin & Erythromycin linked to cardiac sudden deaths

[Guest guest]

Zith (at the molecular level) is different than Clarithromycin and

Erythromycon - even though it's in the same family, it is not

metabolized thru the P450 (liver enzymes), but rather thru biliary

excretion. So the metabolites will be different.

Whether or not, this difference also alters it in the way it

affects the Q interval of the heart will have to be researched..

there's probably literature on it...

Barb

> will azithromycin also cause sudden death since its in the same

> class of antibiotics as the two drugs:

> 1. Erythromycin (Brand names: E-Base; E-Mycin; E.E.S.;

> Ery-Tab; ERYC; EryPed; Erythrocin; Ilosone)

> 2. Clarithromycin (Brand name: Biaxin)

>

> Anyone have any info?

> ------------------------

>

> From: " Mycoplasma Registry GWI & CFS " <mycoreg@j...>

> Date: Fri May 13, 2005 6:40 pm

> Subject: Mycoplasma Registry Reports-antibiotic

warning:erythromycin

> & clarithromycin

>

> * * * * * * * * * * * * * * * * * * * * * * * * * * *

> MYCOPLASMA REGISTRY REPORTS

> for gulf war syndrome & chronic fatigue syndrome

> © Dudley & Leslee Dudley 2005. All rights reserved.

> MycoplasmaRegistry/ MycoReg@

> * * * * * * * * * * * * * * * * * * * * * * * * * * *

>

> Seven drugs interfere with electrical activity controlling the

> heartbeat and may increase risk of sudden cardiac death. (see

> article and abstract below: 'Antibiotics linked to sudden deaths'

> and 'Non-cardiac QTc-prolonging drugs and the risk of sudden cardiac

> death')

>

> Two of the drugs are used to treat mycoplasmal infections:

> Etrythromycin is prescribed to treat M. pneumoniae and M. penetrans.

> Clarithromycin is prescribed to treat M. pneumoniae, M. penetrans

and

> M. purim.

>

> RISK LIST:

> 1. Erythromycin (Brand names: E-Base; E-Mycin; E.E.S.;

> Ery-Tab; ERYC; EryPed; Erythrocin; Ilosone)

> 2. Clarithromycin (Brand name: Biaxin)

> 3. Cisapride (Brand names: Propulsid, Prepulsid)

> 4. Domperidone (Brand names: Motilium®)

> 5. Chlorpromazine (Brand name: Largactil, Thorazine)

> 6. Haloperidol (Brand names: Haldol, Haldol Decanoate,

> Apo-Haloperidol, Haldol, Haldol LA, Novo-Peridol,

> Peridol, PMS Haloperidol)

> 7. Pimozide (Brand name: Orap)

>

>

> Dudley & Leslee Dudley © 2005 .

>

> * * * * * * * * * * * * * * * * * * * * * * * * * * *

>

> Antibiotics linked to sudden deaths

> Daily Mail - UK, UK - May 11, 2005

>

http://www.dailymail.co.uk/pages/live/articles/health/healthmain.html?

> in_article_id=348255 & in_page_id=1774

>

> A range of commonly prescribed drugs including antibiotics may be

> responsible for around 15,000 sudden deaths each year in Europe and

> the United States, researchers claim.

>

> The drugs interfere with electrical activity controlling the

> heartbeat. A study in the Netherlands found they were associated

with

> a three-fold increased risk of sudden death due to cardiac arrest.

>

> Two of the drugs are the antibiotics erythromycin and

> clarithromycin. Others on the risk list are cisapride domperidone

> used to treat gastro-intestinal conditions, and the anti-psychotic

> medications chlorpromazine, haloperidol and pimozide.

>

> All prolong the heart's QTc interval - a measurement of the

> electrical activity linked to the contraction of heart muscle cells.

> Drugs that increase the QTc interval can cause life-threatening

> disruptions of heart rhythms.

>

> Widespread research

> The findings emerged from a study of 775 cases of sudden heart

death.

>

> Researchers found that the seven drugs were probably responsible for

> 320 of these deaths.

>

> This equated to about 15,000 deaths per year across Europe and the

> United States.

>

> But the study's senior author, Dr Bruno Stricker, from the Erasmus

> Medical Centre in Rotterdam, said that although the findings were

> significant, it was important to keep them in proportion.

>

> It was normal to expect one or two sudden cardiac deaths per

thousand

> of the population each year in Western countries.

>

> The risk for people taking the drugs rose to around three per

> thousand.

>

> Vital treatments

> " These drugs are vital treatments for serious conditions in many

> cases, so it is essential that patients should not stop taking them

> on their own initiative, " said Dr Stricker, who is also a senior

> medical officer at the Inspectorate for Healthcare in The Hague.

>

> " If they are concerned they should talk to their doctor. "

>

> The drugs have all previously been implicated in abnormal heart

> rhythms (arrhythmia). But the new study is thought to be the first

to

> investigate links with sudden death.

>

> The findings appeared in the European Heart Journal.

> 2005 Associated Newspapers Ltd · Terms & Conditions ·

>

> * * * * * * * * * * * * * * * * * * * * * * * * * * *

>

> Non-cardiac QTc-prolonging drugs and the risk of sudden cardiac

death

> http://eurheartj.oupjournals.org/cgi/content/abstract/ehi312v1

> European Heart Journal Advance Access published online on May 11,

> 2005. European Heart Journal, doi:10.1093/eurheartj/ehi312

> European Heart Journal © The European Society of Cardiology 2005;

All

> rights reserved. Received February 6, 2005, Revised April 1, 2005,

> Accepted April 7, 2005

> Sabine M.J.M. Straus 1, Miriam C.J.M. Sturkenboom 2, Gysèle S.

> Bleumink 3, Jeanne P. Dieleman 2, Johan van der Lei 4, Pieter A. de

> Graeff 5, Jan Herre Kingma 6, and Bruno H.Ch. Stricker 7*

> 1 Pharmaco-Epidemiology Unit, Departments of Epidemiology and

> Biostatistics and Internal Medicine, Erasmus Medical Center, PO Box

> 1738, 3000 DR Rotterdam, The Netherlands; Department of Medical

> Informatics, Erasmus Medical Center, 3000 DR Rotterdam, The

> Netherlands; Medicines Evaluation Board, The Hague, The Netherlands

> 2 Pharmaco-Epidemiology Unit, Departments of Epidemiology and

> Biostatistics and Internal Medicine, Erasmus Medical Center, PO Box

> 1738, 3000 DR Rotterdam, The Netherlands; Department of Medical

> Informatics, Erasmus Medical Center, 3000 DR Rotterdam, The

> Netherlands

> 3 Pharmaco-Epidemiology Unit, Departments of Epidemiology and

> Biostatistics and Internal Medicine, Erasmus Medical Center, PO Box

> 1738, 3000 DR Rotterdam, The Netherlands; Inspectorate for Health

> Care, The Hague, The Netherlands

> 4 Department of Medical Informatics, Erasmus Medical Center, 3000 DR

> Rotterdam, The Netherlands

> 5 Medicines Evaluation Board, The Hague, The Netherlands; Department

> of Clinical Pharmacology, University of Groningen, Groningen, The

> Netherlands

> 6 Inspectorate for Health Care, The Hague, The Netherlands;

> Department of Clinical Pharmacology, University of Groningen,

> Groningen, The Netherlands

> 7 Pharmaco-Epidemiology Unit, Departments of Epidemiology and

> Biostatistics and Internal Medicine, Erasmus Medical Center, PO Box

> 1738, 3000 DR Rotterdam, The Netherlands; Inspectorate for Health

> Care, The Hague, The Netherlands

> * To whom correspondence should be addressed.

> Bruno H.Ch. Stricker, E-mail: b.stricker@

>

> ABSTRACT

>

> Aims: To assess the association between the use of non-cardiac QTc-

> prolonging drugs and the risk of sudden cardiac death.

>

> Methods and results: A population-based case-control study was

> performed in the Integrated Primary Care Information (IPCI) project,

> a longitudinal observational database with complete medical records

> from more than 500 000 persons. All deaths between 1 January 1995

and

> 1 September 2003 were reviewed. Sudden cardiac death was classified

> based on the time between onset of cardiovascular symptoms and

death.

> For each case, up to 10 random controls were matched for age,

gender,

> date of sudden death, and general practice. The exposure of interest

> was the use of non-cardiac QTc-prolonging drugs. Exposure at the

> index date was categorized into three mutually exclusive groups of

> current use, past use, and non-use. The study population comprised

> 775 cases of sudden cardiac death and 6297 matched controls. Current

> use of any non-cardiac QTc-prolonging drug was associated with a

> significantly increased risk of sudden cardiac death (adjusted OR:

> 2.7; 95% CI: 1.6-4.7). The risk of death was highest in women and in

> recent starters.

>

> Conclusion: The use of non-cardiac QTc-prolonging drugs in a

> general population is associated with an increased risk of sudden

> cardiac death.

>

> antibiotic warning:erythromycin & clarithromycin linked to sudden

> deaths-study

>

> * * * * * * * * * * * * * * * * * * * * * * * * * * *

> FREE BROCHURE: " How to Get an Accurate Polymerase Chain Reaction

(PRC)

> Blood Test for Mycoplasmal and Other Infections-with a List of

> International Laboratories " © by and Leslee Dudley

> is sent automatically and immediately to all new subscribers. It is

> updated with current information and the new version is posted to

the

> Mycoplasma Registry Reports & News list each month.

> MycoplasmaRegistry-subscribe

>

> FAIR USE: In accordance with Title 17 U.S.C. Section 107, this

> material is distributed without profit to those who have expressed a

> prior interest in receiving the included information for research

and

> educational purposes. The Mycoplasma Registry has no affiliation

with

> the originator of this article nor is the Mycoplasma Registry

> endorsed or sponsored by the originator. If you wish to use

> copyrighted material from this site for purposes of your own that go

> beyond 'fair use', you must obtain permission from the copyright

> owner.

> * * * * * * * * * * * * * * * * * * * * * * * * * * *

[Guest guest]

A bit of serendipity here.

I restarted Ketek yesterday after a 2 week rest and had a 3 1/2

hour " episode " of very frequent, irregularly irregular heart beats.

This was about 2 hours after my 1st dose.

Historically I have had 'palpitations' for over 25 years and have

seen these on ECG as PVC's. I have no idea what yesterday's were, (ie

QT interval) but they felt like missed beats.

I wonder if Ketek was included (or is it too new) and also if it is

metabolized in a similar way?

Robyn

> > will azithromycin also cause sudden death since its in the same

> > class of antibiotics as the two drugs:

> > 1. Erythromycin (Brand names: E-Base; E-Mycin; E.E.S.;

> > Ery-Tab; ERYC; EryPed; Erythrocin; Ilosone)

> > 2. Clarithromycin (Brand name: Biaxin)

> >

> > Anyone have any info?

> > ------------------------

> >

> > From: " Mycoplasma Registry GWI & CFS " <mycoreg@j...>

> > Date: Fri May 13, 2005 6:40 pm

> > Subject: Mycoplasma Registry Reports-antibiotic

> warning:erythromycin

> > & clarithromycin

> >

> > * * * * * * * * * * * * * * * * * * * * * * * * * * *

> > MYCOPLASMA REGISTRY REPORTS

> > for gulf war syndrome & chronic fatigue syndrome

> > © Dudley & Leslee Dudley 2005. All rights reserved.

> > MycoplasmaRegistry/ MycoReg@

> > * * * * * * * * * * * * * * * * * * * * * * * * * * *

> >

> > Seven drugs interfere with electrical activity controlling the

> > heartbeat and may increase risk of sudden cardiac death. (see

> > article and abstract below: 'Antibiotics linked to sudden deaths'

> > and 'Non-cardiac QTc-prolonging drugs and the risk of sudden

cardiac

> > death')

> >

> > Two of the drugs are used to treat mycoplasmal infections:

> > Etrythromycin is prescribed to treat M. pneumoniae and M.

penetrans.

> > Clarithromycin is prescribed to treat M. pneumoniae, M. penetrans

> and

> > M. purim.

> >

> > RISK LIST:

> > 1. Erythromycin (Brand names: E-Base; E-Mycin; E.E.S.;

> > Ery-Tab; ERYC; EryPed; Erythrocin; Ilosone)

> > 2. Clarithromycin (Brand name: Biaxin)

> > 3. Cisapride (Brand names: Propulsid, Prepulsid)

> > 4. Domperidone (Brand names: Motilium®)

> > 5. Chlorpromazine (Brand name: Largactil, Thorazine)

> > 6. Haloperidol (Brand names: Haldol, Haldol Decanoate,

> > Apo-Haloperidol, Haldol, Haldol LA, Novo-Peridol,

> > Peridol, PMS Haloperidol)

> > 7. Pimozide (Brand name: Orap)

> >

> >

> > Dudley & Leslee Dudley © 2005 .

> >

> > * * * * * * * * * * * * * * * * * * * * * * * * * * *

> >

> > Antibiotics linked to sudden deaths

> > Daily Mail - UK, UK - May 11, 2005

> >

>

http://www.dailymail.co.uk/pages/live/articles/health/healthmain.html?

> > in_article_id=348255 & in_page_id=1774

> >

> > A range of commonly prescribed drugs including antibiotics may be

> > responsible for around 15,000 sudden deaths each year in Europe

and

> > the United States, researchers claim.

> >

> > The drugs interfere with electrical activity controlling the

> > heartbeat. A study in the Netherlands found they were associated

> with

> > a three-fold increased risk of sudden death due to cardiac arrest.

> >

> > Two of the drugs are the antibiotics erythromycin and

> > clarithromycin. Others on the risk list are cisapride domperidone

> > used to treat gastro-intestinal conditions, and the anti-psychotic

> > medications chlorpromazine, haloperidol and pimozide.

> >

> > All prolong the heart's QTc interval - a measurement of the

> > electrical activity linked to the contraction of heart muscle

cells.

> > Drugs that increase the QTc interval can cause life-threatening

> > disruptions of heart rhythms.

> >

> > Widespread research

> > The findings emerged from a study of 775 cases of sudden heart

> death.

> >

> > Researchers found that the seven drugs were probably responsible

for

> > 320 of these deaths.

> >

> > This equated to about 15,000 deaths per year across Europe and the

> > United States.

> >

> > But the study's senior author, Dr Bruno Stricker, from the Erasmus

> > Medical Centre in Rotterdam, said that although the findings were

> > significant, it was important to keep them in proportion.

> >

> > It was normal to expect one or two sudden cardiac deaths per

> thousand

> > of the population each year in Western countries.

> >

> > The risk for people taking the drugs rose to around three per

> > thousand.

> >

> > Vital treatments

> > " These drugs are vital treatments for serious conditions in many

> > cases, so it is essential that patients should not stop taking

them

> > on their own initiative, " said Dr Stricker, who is also a senior

> > medical officer at the Inspectorate for Healthcare in The Hague.

> >

> > " If they are concerned they should talk to their doctor. "

> >

> > The drugs have all previously been implicated in abnormal heart

> > rhythms (arrhythmia). But the new study is thought to be the

first

> to

> > investigate links with sudden death.

> >

> > The findings appeared in the European Heart Journal.

> > 2005 Associated Newspapers Ltd · Terms & Conditions ·

> >

> > * * * * * * * * * * * * * * * * * * * * * * * * * * *

> >

> > Non-cardiac QTc-prolonging drugs and the risk of sudden cardiac

> death

> > http://eurheartj.oupjournals.org/cgi/content/abstract/ehi312v1

> > European Heart Journal Advance Access published online on May 11,

> > 2005. European Heart Journal, doi:10.1093/eurheartj/ehi312

> > European Heart Journal © The European Society of Cardiology 2005;

> All

> > rights reserved. Received February 6, 2005, Revised April 1, 2005,

> > Accepted April 7, 2005

> > Sabine M.J.M. Straus 1, Miriam C.J.M. Sturkenboom 2, Gysèle S.

> > Bleumink 3, Jeanne P. Dieleman 2, Johan van der Lei 4, Pieter A.

de

> > Graeff 5, Jan Herre Kingma 6, and Bruno H.Ch. Stricker 7*

> > 1 Pharmaco-Epidemiology Unit, Departments of Epidemiology and

> > Biostatistics and Internal Medicine, Erasmus Medical Center, PO

Box

> > 1738, 3000 DR Rotterdam, The Netherlands; Department of Medical

> > Informatics, Erasmus Medical Center, 3000 DR Rotterdam, The

> > Netherlands; Medicines Evaluation Board, The Hague, The

Netherlands

> > 2 Pharmaco-Epidemiology Unit, Departments of Epidemiology and

> > Biostatistics and Internal Medicine, Erasmus Medical Center, PO

Box

> > 1738, 3000 DR Rotterdam, The Netherlands; Department of Medical

> > Informatics, Erasmus Medical Center, 3000 DR Rotterdam, The

> > Netherlands

> > 3 Pharmaco-Epidemiology Unit, Departments of Epidemiology and

> > Biostatistics and Internal Medicine, Erasmus Medical Center, PO

Box

> > 1738, 3000 DR Rotterdam, The Netherlands; Inspectorate for Health

> > Care, The Hague, The Netherlands

> > 4 Department of Medical Informatics, Erasmus Medical Center, 3000

DR

> > Rotterdam, The Netherlands

> > 5 Medicines Evaluation Board, The Hague, The Netherlands;

Department

> > of Clinical Pharmacology, University of Groningen, Groningen, The

> > Netherlands

> > 6 Inspectorate for Health Care, The Hague, The Netherlands;

> > Department of Clinical Pharmacology, University of Groningen,

> > Groningen, The Netherlands

> > 7 Pharmaco-Epidemiology Unit, Departments of Epidemiology and

> > Biostatistics and Internal Medicine, Erasmus Medical Center, PO

Box

> > 1738, 3000 DR Rotterdam, The Netherlands; Inspectorate for Health

> > Care, The Hague, The Netherlands

> > * To whom correspondence should be addressed.

> > Bruno H.Ch. Stricker, E-mail: b.stricker@

> >

> > ABSTRACT

> >

> > Aims: To assess the association between the use of non-cardiac

QTc-

> > prolonging drugs and the risk of sudden cardiac death.

> >

> > Methods and results: A population-based case-control study was

> > performed in the Integrated Primary Care Information (IPCI)

project,

> > a longitudinal observational database with complete medical

records

> > from more than 500 000 persons. All deaths between 1 January 1995

> and

> > 1 September 2003 were reviewed. Sudden cardiac death was

classified

> > based on the time between onset of cardiovascular symptoms and

> death.

> > For each case, up to 10 random controls were matched for age,

> gender,

> > date of sudden death, and general practice. The exposure of

interest

> > was the use of non-cardiac QTc-prolonging drugs. Exposure at the

> > index date was categorized into three mutually exclusive groups of

> > current use, past use, and non-use. The study population comprised

> > 775 cases of sudden cardiac death and 6297 matched controls.

Current

> > use of any non-cardiac QTc-prolonging drug was associated with a

> > significantly increased risk of sudden cardiac death (adjusted OR:

> > 2.7; 95% CI: 1.6-4.7). The risk of death was highest in women and

in

> > recent starters.

> >

> > Conclusion: The use of non-cardiac QTc-prolonging drugs in a

> > general population is associated with an increased risk of sudden

> > cardiac death.

> >

> > antibiotic warning:erythromycin & clarithromycin linked to sudden

> > deaths-study

> >

> > * * * * * * * * * * * * * * * * * * * * * * * * * * *

> > FREE BROCHURE: " How to Get an Accurate Polymerase Chain Reaction

> (PRC)

> > Blood Test for Mycoplasmal and Other Infections-with a List of

> > International Laboratories " © by and Leslee Dudley

> > is sent automatically and immediately to all new subscribers. It

is

> > updated with current information and the new version is posted to

> the

> > Mycoplasma Registry Reports & News list each month.

> > MycoplasmaRegistry-subscribe

> >

> > FAIR USE: In accordance with Title 17 U.S.C. Section 107, this

> > material is distributed without profit to those who have

expressed a

> > prior interest in receiving the included information for research

> and

> > educational purposes. The Mycoplasma Registry has no affiliation

> with

> > the originator of this article nor is the Mycoplasma Registry

> > endorsed or sponsored by the originator. If you wish to use

> > copyrighted material from this site for purposes of your own that

go

> > beyond 'fair use', you must obtain permission from the copyright

> > owner.

> > * * * * * * * * * * * * * * * * * * * * * * * * * * *

[Guest guest]

Hmmm, I've had these palpitation episodes frequently when starting

new abx. But the absolute worst for me is Minocycline. It makes my

heart crazy. I thought I was having a heart attack one night in the

early days of the un-mentionable protocol (aka the unMP) :-). It was

so bad, I couldn't even call for help. Next day, I was so scared by

what had happened to me that I went to an ER for an EKG.

What's interesting to me, and what I think is really significant, is

that the palps were WAY worse on low dose mino than they ever were

when I was doing i.v. mino at full dose. I think it means the bugs

affecting my heart were being stirred up but not killed with the low

dose mino. High dose mino gave me some palps, but mainly made me

feel like I was dying, --just dying in general, not dying of a heart

attack.

In my mind, these things are so complex, it's hard to know if its'

the abx that are actually causing the heart disease that leads to

heart attacks, or whether they are simply stirring something up

that's already there. I hope this isn't the beginning of the end,

where ALL abx are discovered to lead to heart disease. :-(

Then it'll be like chemo. A race to see what kills you first. The

disease, or the treatment.

penny

> > > will azithromycin also cause sudden death since its in the

same

> > > class of antibiotics as the two drugs:

> > > 1. Erythromycin (Brand names: E-Base; E-Mycin; E.E.S.;

> > > Ery-Tab; ERYC; EryPed; Erythrocin; Ilosone)

> > > 2. Clarithromycin (Brand name: Biaxin)

> > >

> > > Anyone have any info?

> > > ------------------------

> > >

> > > From: " Mycoplasma Registry GWI & CFS " <mycoreg@j...>

> > > Date: Fri May 13, 2005 6:40 pm

> > > Subject: Mycoplasma Registry Reports-antibiotic

> > warning:erythromycin

> > > & clarithromycin

> > >

> > > * * * * * * * * * * * * * * * * * * * * * * * * * * *

> > > MYCOPLASMA REGISTRY REPORTS

> > > for gulf war syndrome & chronic fatigue syndrome

> > > © Dudley & Leslee Dudley 2005. All rights reserved.

> > > MycoplasmaRegistry/ MycoReg@

> > > * * * * * * * * * * * * * * * * * * * * * * * * * * *

> > >

> > > Seven drugs interfere with electrical activity controlling the

> > > heartbeat and may increase risk of sudden cardiac death. (see

> > > article and abstract below: 'Antibiotics linked to sudden

deaths'

> > > and 'Non-cardiac QTc-prolonging drugs and the risk of sudden

> cardiac

> > > death')

> > >

> > > Two of the drugs are used to treat mycoplasmal infections:

> > > Etrythromycin is prescribed to treat M. pneumoniae and M.

> penetrans.

> > > Clarithromycin is prescribed to treat M. pneumoniae, M.

penetrans

> > and

> > > M. purim.

> > >

> > > RISK LIST:

> > > 1. Erythromycin (Brand names: E-Base; E-Mycin; E.E.S.;

> > > Ery-Tab; ERYC; EryPed; Erythrocin; Ilosone)

> > > 2. Clarithromycin (Brand name: Biaxin)

> > > 3. Cisapride (Brand names: Propulsid, Prepulsid)

> > > 4. Domperidone (Brand names: Motilium®)

> > > 5. Chlorpromazine (Brand name: Largactil, Thorazine)

> > > 6. Haloperidol (Brand names: Haldol, Haldol Decanoate,

> > > Apo-Haloperidol, Haldol, Haldol LA, Novo-Peridol,

> > > Peridol, PMS Haloperidol)

> > > 7. Pimozide (Brand name: Orap)

> > >

> > >

> > > Dudley & Leslee Dudley © 2005 .

> > >

> > > * * * * * * * * * * * * * * * * * * * * * * * * * * *

> > >

> > > Antibiotics linked to sudden deaths

> > > Daily Mail - UK, UK - May 11, 2005

> > >

> >

>

http://www.dailymail.co.uk/pages/live/articles/health/healthmain.html

?

> > > in_article_id=348255 & in_page_id=1774

> > >

> > > A range of commonly prescribed drugs including antibiotics may

be

> > > responsible for around 15,000 sudden deaths each year in

Europe

> and

> > > the United States, researchers claim.

> > >

> > > The drugs interfere with electrical activity controlling the

> > > heartbeat. A study in the Netherlands found they were

associated

> > with

> > > a three-fold increased risk of sudden death due to cardiac

arrest.

> > >

> > > Two of the drugs are the antibiotics erythromycin and

> > > clarithromycin. Others on the risk list are cisapride

domperidone

> > > used to treat gastro-intestinal conditions, and the anti-

psychotic

> > > medications chlorpromazine, haloperidol and pimozide.

> > >

> > > All prolong the heart's QTc interval - a measurement of the

> > > electrical activity linked to the contraction of heart muscle

> cells.

> > > Drugs that increase the QTc interval can cause life-threatening

> > > disruptions of heart rhythms.

> > >

> > > Widespread research

> > > The findings emerged from a study of 775 cases of sudden heart

> > death.

> > >

> > > Researchers found that the seven drugs were probably

responsible

> for

> > > 320 of these deaths.

> > >

> > > This equated to about 15,000 deaths per year across Europe and

the

> > > United States.

> > >

> > > But the study's senior author, Dr Bruno Stricker, from the

Erasmus

> > > Medical Centre in Rotterdam, said that although the findings

were

> > > significant, it was important to keep them in proportion.

> > >

> > > It was normal to expect one or two sudden cardiac deaths per

> > thousand

> > > of the population each year in Western countries.

> > >

> > > The risk for people taking the drugs rose to around three per

> > > thousand.

> > >

> > > Vital treatments

> > > " These drugs are vital treatments for serious conditions in

many

> > > cases, so it is essential that patients should not stop taking

> them

> > > on their own initiative, " said Dr Stricker, who is also a

senior

> > > medical officer at the Inspectorate for Healthcare in The

Hague.

> > >

> > > " If they are concerned they should talk to their doctor. "

> > >

> > > The drugs have all previously been implicated in abnormal heart

> > > rhythms (arrhythmia). But the new study is thought to be the

> first

> > to

> > > investigate links with sudden death.

> > >

> > > The findings appeared in the European Heart Journal.

> > > 2005 Associated Newspapers Ltd · Terms & Conditions ·

> > >

> > > * * * * * * * * * * * * * * * * * * * * * * * * * * *

> > >

> > > Non-cardiac QTc-prolonging drugs and the risk of sudden

cardiac

> > death

> > > http://eurheartj.oupjournals.org/cgi/content/abstract/ehi312v1

> > > European Heart Journal Advance Access published online on May

11,

> > > 2005. European Heart Journal, doi:10.1093/eurheartj/ehi312

> > > European Heart Journal © The European Society of Cardiology

2005;

> > All

> > > rights reserved. Received February 6, 2005, Revised April 1,

2005,

> > > Accepted April 7, 2005

> > > Sabine M.J.M. Straus 1, Miriam C.J.M. Sturkenboom 2, Gysèle S.

> > > Bleumink 3, Jeanne P. Dieleman 2, Johan van der Lei 4, Pieter

A.

> de

> > > Graeff 5, Jan Herre Kingma 6, and Bruno H.Ch. Stricker 7*

> > > 1 Pharmaco-Epidemiology Unit, Departments of Epidemiology and

> > > Biostatistics and Internal Medicine, Erasmus Medical Center,

PO

> Box

> > > 1738, 3000 DR Rotterdam, The Netherlands; Department of Medical

> > > Informatics, Erasmus Medical Center, 3000 DR Rotterdam, The

> > > Netherlands; Medicines Evaluation Board, The Hague, The

> Netherlands

> > > 2 Pharmaco-Epidemiology Unit, Departments of Epidemiology and

> > > Biostatistics and Internal Medicine, Erasmus Medical Center,

PO

> Box

> > > 1738, 3000 DR Rotterdam, The Netherlands; Department of Medical

> > > Informatics, Erasmus Medical Center, 3000 DR Rotterdam, The

> > > Netherlands

> > > 3 Pharmaco-Epidemiology Unit, Departments of Epidemiology and

> > > Biostatistics and Internal Medicine, Erasmus Medical Center,

PO

> Box

> > > 1738, 3000 DR Rotterdam, The Netherlands; Inspectorate for

Health

> > > Care, The Hague, The Netherlands

> > > 4 Department of Medical Informatics, Erasmus Medical Center,

3000

> DR

> > > Rotterdam, The Netherlands

> > > 5 Medicines Evaluation Board, The Hague, The Netherlands;

> Department

> > > of Clinical Pharmacology, University of Groningen, Groningen,

The

> > > Netherlands

> > > 6 Inspectorate for Health Care, The Hague, The Netherlands;

> > > Department of Clinical Pharmacology, University of Groningen,

> > > Groningen, The Netherlands

> > > 7 Pharmaco-Epidemiology Unit, Departments of Epidemiology and

> > > Biostatistics and Internal Medicine, Erasmus Medical Center,

PO

> Box

> > > 1738, 3000 DR Rotterdam, The Netherlands; Inspectorate for

Health

> > > Care, The Hague, The Netherlands

> > > * To whom correspondence should be addressed.

> > > Bruno H.Ch. Stricker, E-mail: b.stricker@

> > >

> > > ABSTRACT

> > >

> > > Aims: To assess the association between the use of non-cardiac

> QTc-

> > > prolonging drugs and the risk of sudden cardiac death.

> > >

> > > Methods and results: A population-based case-control study was

> > > performed in the Integrated Primary Care Information (IPCI)

> project,

> > > a longitudinal observational database with complete medical

> records

> > > from more than 500 000 persons. All deaths between 1 January

1995

> > and

> > > 1 September 2003 were reviewed. Sudden cardiac death was

> classified

> > > based on the time between onset of cardiovascular symptoms and

> > death.

> > > For each case, up to 10 random controls were matched for age,

> > gender,

> > > date of sudden death, and general practice. The exposure of

> interest

> > > was the use of non-cardiac QTc-prolonging drugs. Exposure at

the

> > > index date was categorized into three mutually exclusive

groups of

> > > current use, past use, and non-use. The study population

comprised

> > > 775 cases of sudden cardiac death and 6297 matched controls.

> Current

> > > use of any non-cardiac QTc-prolonging drug was associated with

a

> > > significantly increased risk of sudden cardiac death (adjusted

OR:

> > > 2.7; 95% CI: 1.6-4.7). The risk of death was highest in women

and

> in

> > > recent starters.

> > >

> > > Conclusion: The use of non-cardiac QTc-prolonging drugs in a

> > > general population is associated with an increased risk of

sudden

> > > cardiac death.

> > >

> > > antibiotic warning:erythromycin & clarithromycin linked to

sudden

> > > deaths-study

> > >

> > > * * * * * * * * * * * * * * * * * * * * * * * * * * *

> > > FREE BROCHURE: " How to Get an Accurate Polymerase Chain

Reaction

> > (PRC)

> > > Blood Test for Mycoplasmal and Other Infections-with a List of

> > > International Laboratories " © by and Leslee Dudley

> > > is sent automatically and immediately to all new subscribers.

It

> is

> > > updated with current information and the new version is posted

to

> > the

> > > Mycoplasma Registry Reports & News list each month.

> > > MycoplasmaRegistry-subscribe

> > >

> > > FAIR USE: In accordance with Title 17 U.S.C. Section 107, this

> > > material is distributed without profit to those who have

> expressed a

> > > prior interest in receiving the included information for

research

> > and

> > > educational purposes. The Mycoplasma Registry has no

affiliation

> > with

> > > the originator of this article nor is the Mycoplasma Registry

> > > endorsed or sponsored by the originator. If you wish to use

> > > copyrighted material from this site for purposes of your own

that

> go

> > > beyond 'fair use', you must obtain permission from the

copyright

> > > owner.

> > > * * * * * * * * * * * * * * * * * * * * * * * * * * *

[Guest guest]

I am thinking this all might be eased slightly with added potassium.

This is a hunch. Not any data to back it up. I think many of us are low

on many elements potassium being one of them. When I started to take

B12 in high doses I could feel my Potassium(K) going to the floor. I

started to add k and it all made a lot of difference. I since see the

effect k has on the heart, especially after the benicar disaster. B4

this my heart was as strong as an ox, but this last 6 months it has

felt much weaker at times. Hoping that the detox from the bs will make

all the difference. I have stopped taking k and might ad it back in

again for a while to see how it gels.

> A bit of serendipity here.

>

> I restarted Ketek yesterday after a 2 week rest and had a 3 1/2

> hour " episode " of very frequent, irregularly irregular heart beats.

> This was about 2 hours after my 1st dose.

>

> Historically I have had 'palpitations' for over 25 years and have

> seen these on ECG as PVC's. I have no idea what yesterday's were, (ie

> QT interval) but they felt like missed beats.

>

> I wonder if Ketek was included (or is it too new) and also if it is

> metabolized in a similar way?

>

> Robyn

>

>

> > > will azithromycin also cause sudden death since its in the same

> > > class of antibiotics as the two drugs:

> > > 1. Erythromycin (Brand names: E-Base; E-Mycin; E.E.S.;

> > > Ery-Tab; ERYC; EryPed; Erythrocin; Ilosone)

> > > 2. Clarithromycin (Brand name: Biaxin)

> > >

> > > Anyone have any info?

> > > ------------------------

> > >

> > > From: " Mycoplasma Registry GWI & CFS " <mycoreg@j...>

> > > Date: Fri May 13, 2005  6:40 pm

> > > Subject: Mycoplasma Registry Reports-antibiotic

> > warning:erythromycin

> > > & clarithromycin

> > >

> > > * * * * * * * * * * * * * * * * * * * * * * * * * * *

> > > MYCOPLASMA REGISTRY REPORTS

> > > for gulf war syndrome & chronic fatigue syndrome

> > > © Dudley & Leslee Dudley 2005. All rights reserved.

> > > MycoplasmaRegistry/ MycoReg@

> > > * * * * * * * * * * * * * * * * * * * * * * * * * * *

> > >

> > > Seven drugs interfere with electrical activity controlling the

> > > heartbeat and may increase risk of sudden cardiac death. (see

> > > article and abstract below: 'Antibiotics linked to sudden deaths'

> > > and 'Non-cardiac QTc-prolonging drugs and the risk of sudden

> cardiac

> > > death')

> > >

> > > Two of the drugs are used to treat mycoplasmal infections:

> > > Etrythromycin is prescribed to treat M. pneumoniae and M.

> penetrans.

> > > Clarithromycin is prescribed to treat M. pneumoniae, M. penetrans

> > and

> > > M. purim.

> > >

> > > RISK LIST:

> > > 1. Erythromycin (Brand names: E-Base; E-Mycin; E.E.S.;

> > > Ery-Tab; ERYC; EryPed; Erythrocin; Ilosone)

> > > 2. Clarithromycin (Brand name: Biaxin)

> > > 3. Cisapride (Brand names: Propulsid, Prepulsid)

> > > 4. Domperidone (Brand names: Motilium®)

> > > 5. Chlorpromazine (Brand name: Largactil, Thorazine)

> > > 6. Haloperidol (Brand names: Haldol, Haldol Decanoate,

> > > Apo-Haloperidol, Haldol, Haldol LA, Novo-Peridol,

> > > Peridol, PMS Haloperidol)

> > > 7. Pimozide (Brand name: Orap)

> > >

> > >

> > > Dudley & Leslee Dudley © 2005 .

> > >

> > > * * * * * * * * * * * * * * * * * * * * * * * * * * *

> > >

> > > Antibiotics linked to sudden deaths

> > > Daily Mail - UK, UK - May 11, 2005

> > >

> >

> http://www.dailymail.co.uk/pages/live/articles/health/healthmain.html?

> > > in_article_id=348255 & in_page_id=1774

> > >

> > > A range of commonly prescribed drugs including antibiotics may be

> > > responsible for around 15,000 sudden deaths each year in Europe

> and

> > > the United States, researchers claim.

> > >

> > > The drugs interfere with electrical activity controlling the

> > > heartbeat. A study in the Netherlands found they were associated

> > with

> > > a three-fold increased risk of sudden death due to cardiac arrest.

> > >

> > > Two of the drugs are the antibiotics erythromycin and

> > > clarithromycin. Others on the risk list are cisapride domperidone

> > > used to treat gastro-intestinal conditions, and the anti-psychotic

> > > medications chlorpromazine, haloperidol and pimozide.

> > >

> > > All prolong the heart's QTc interval - a measurement of the

> > > electrical activity linked to the contraction of heart muscle

> cells.

> > > Drugs that increase the QTc interval can cause life-threatening

> > > disruptions of heart rhythms.

> > >

> > > Widespread research

> > > The findings emerged from a study of 775 cases of sudden heart

> > death.

> > >

> > > Researchers found that the seven drugs were probably responsible

> for

> > > 320 of these deaths.

> > >

> > > This equated to about 15,000 deaths per year across Europe and the

> > > United States.

> > >

> > > But the study's senior author, Dr Bruno Stricker, from the Erasmus

> > > Medical Centre in Rotterdam, said that although the findings were

> > > significant, it was important to keep them in proportion.

> > >

> > > It was normal to expect one or two sudden cardiac deaths per

> > thousand

> > > of the population each year in Western countries.

> > >

> > > The risk for people taking the drugs rose to around three per

> > > thousand.

> > >

> > > Vital treatments

> > > " These drugs are vital treatments for serious conditions in many

> > > cases, so it is essential that patients should not stop taking

> them

> > > on their own initiative, " said Dr Stricker, who is also a senior

> > > medical officer at the Inspectorate for Healthcare in The Hague.

> > >

> > > " If they are concerned they should talk to their doctor. "

> > >

> > > The drugs have all previously been implicated in abnormal heart

> > > rhythms (arrhythmia). But the new study is thought to be the

> first

> > to

> > > investigate links with sudden death.

> > >

> > > The findings appeared in the European Heart Journal.

> > > 2005 Associated Newspapers Ltd · Terms & Conditions ·

> > >

> > > * * * * * * * * * * * * * * * * * * * * * * * * * * *

> > >

> > > Non-cardiac QTc-prolonging drugs and the risk of sudden cardiac

> > death

> > > http://eurheartj.oupjournals.org/cgi/content/abstract/ehi312v1

> > > European Heart Journal Advance Access published online on May 11,

> > > 2005. European Heart Journal, doi:10.1093/eurheartj/ehi312

> > > European Heart Journal © The European Society of Cardiology 2005;

> > All

> > > rights reserved. Received February 6, 2005, Revised April 1, 2005,

> > > Accepted April 7, 2005

> > > Sabine M.J.M. Straus 1, Miriam C.J.M. Sturkenboom 2, Gysèle S.

> > > Bleumink 3, Jeanne P. Dieleman 2, Johan van der Lei 4, Pieter A.

> de

> > > Graeff 5, Jan Herre Kingma 6, and Bruno H.Ch. Stricker 7*

> > > 1 Pharmaco-Epidemiology Unit, Departments of Epidemiology and

> > > Biostatistics and Internal Medicine, Erasmus Medical Center, PO

> Box

> > > 1738, 3000 DR Rotterdam, The Netherlands; Department of Medical

> > > Informatics, Erasmus Medical Center, 3000 DR Rotterdam, The

> > > Netherlands; Medicines Evaluation Board, The Hague, The

> Netherlands

> > > 2 Pharmaco-Epidemiology Unit, Departments of Epidemiology and

> > > Biostatistics and Internal Medicine, Erasmus Medical Center, PO

> Box

> > > 1738, 3000 DR Rotterdam, The Netherlands; Department of Medical

> > > Informatics, Erasmus Medical Center, 3000 DR Rotterdam, The

> > > Netherlands

> > > 3 Pharmaco-Epidemiology Unit, Departments of Epidemiology and

> > > Biostatistics and Internal Medicine, Erasmus Medical Center, PO

> Box

> > > 1738, 3000 DR Rotterdam, The Netherlands; Inspectorate for Health

> > > Care, The Hague, The Netherlands

> > > 4 Department of Medical Informatics, Erasmus Medical Center, 3000

> DR

> > > Rotterdam, The Netherlands

> > > 5 Medicines Evaluation Board, The Hague, The Netherlands;

> Department

> > > of Clinical Pharmacology, University of Groningen, Groningen, The

> > > Netherlands

> > > 6 Inspectorate for Health Care, The Hague, The Netherlands;

> > > Department of Clinical Pharmacology, University of Groningen,

> > > Groningen, The Netherlands

> > > 7 Pharmaco-Epidemiology Unit, Departments of Epidemiology and

> > > Biostatistics and Internal Medicine, Erasmus Medical Center, PO

> Box

> > > 1738, 3000 DR Rotterdam, The Netherlands; Inspectorate for Health

> > > Care, The Hague, The Netherlands

> > > * To whom correspondence should be addressed.

> > > Bruno H.Ch. Stricker, E-mail: b.stricker@

> > >

> > > ABSTRACT

> > >

> > > Aims: To assess the association between the use of non-cardiac

> QTc-

> > > prolonging drugs and the risk of sudden cardiac death.

> > >

> > > Methods and results: A population-based case-control study was

> > > performed in the Integrated Primary Care Information (IPCI)

> project,

> > > a longitudinal observational database with complete medical

> records

> > > from more than 500 000 persons. All deaths between 1 January 1995

> > and

> > > 1 September 2003 were reviewed. Sudden cardiac death was

> classified

> > > based on the time between onset of cardiovascular symptoms and

> > death.

> > > For each case, up to 10 random controls were matched for age,

> > gender,

> > > date of sudden death, and general practice. The exposure of

> interest

> > > was the use of non-cardiac QTc-prolonging drugs. Exposure at the

> > > index date was categorized into three mutually exclusive groups of

> > > current use, past use, and non-use. The study population comprised

> > > 775 cases of sudden cardiac death and 6297 matched controls.

> Current

> > > use of any non-cardiac QTc-prolonging drug was associated with a

> > > significantly increased risk of sudden cardiac death (adjusted OR:

> > > 2.7; 95% CI: 1.6-4.7). The risk of death was highest in women and

> in

> > > recent starters.

> > >

> > > Conclusion: The use of non-cardiac QTc-prolonging drugs in a

> > > general population is associated with an increased risk of sudden

> > > cardiac death.

> > >

> > > antibiotic warning:erythromycin & clarithromycin linked to sudden

> > > deaths-study

> > >

> > > * * * * * * * * * * * * * * * * * * * * * * * * * * *

> > > FREE BROCHURE: " How to Get an Accurate Polymerase Chain Reaction

> > (PRC)

> > > Blood Test for Mycoplasmal and Other Infections-with a List of

> > > International Laboratories " © by and Leslee Dudley

> > > is sent automatically and immediately to all new subscribers. It

> is

> > > updated with current information and the new version is posted to

> > the

> > > Mycoplasma Registry Reports & News list each month.

> > > MycoplasmaRegistry-subscribe

> > >

> > > FAIR USE: In accordance with Title 17 U.S.C. Section 107, this

> > > material is distributed without profit to those who have

> expressed a

> > > prior interest in receiving the included information for research

> > and

> > > educational purposes. The Mycoplasma Registry has no affiliation

> > with

> > > the originator of this article nor is the Mycoplasma Registry

> > > endorsed or sponsored by the originator. If you wish to use

> > > copyrighted material from this site for purposes of your own that

> go

> > > beyond 'fair use', you must obtain permission from the copyright

> > > owner.

> > > * * * * * * * * * * * * * * * * * * * * * * * * * * *

>

>

>

>

[Guest guest]

Bleu,

Why are you doing K again? Doesn't it have a blood thickening effect?

Here's a tip. If your heart's acting up, grab a glass of v-8 which

is very high in Potassium (close to 600mg in 6 oz). If you notice an

immediate improvement, you'll know if potassium's a factor. Also, if

you get a little energy boost from the V-8, it could mean your

electrolytes are off, as V-8 has a lot of good stuff in it.

penny

> > > > will azithromycin also cause sudden death since its in the

same

> > > > class of antibiotics as the two drugs:

> > > > 1. Erythromycin (Brand names: E-Base; E-Mycin; E.E.S.;

> > > > Ery-Tab; ERYC; EryPed; Erythrocin; Ilosone)

> > > > 2. Clarithromycin (Brand name: Biaxin)

> > > >

> > > > Anyone have any info?

> > > > ------------------------

> > > >

> > > > From: " Mycoplasma Registry GWI & CFS " <mycoreg@j...>

> > > > Date: Fri May 13, 2005  6:40 pm

> > > > Subject: Mycoplasma Registry Reports-antibiotic

> > > warning:erythromycin

> > > > & clarithromycin

> > > >

> > > > * * * * * * * * * * * * * * * * * * * * * * * * * * *

> > > > MYCOPLASMA REGISTRY REPORTS

> > > > for gulf war syndrome & chronic fatigue syndrome

> > > > © Dudley & Leslee Dudley 2005. All rights reserved.

> > > > MycoplasmaRegistry/ MycoReg@

> > > > * * * * * * * * * * * * * * * * * * * * * * * * * * *

> > > >

> > > > Seven drugs interfere with electrical activity controlling

the

> > > > heartbeat and may increase risk of sudden cardiac death.

(see

> > > > article and abstract below: 'Antibiotics linked to sudden

deaths'

> > > > and 'Non-cardiac QTc-prolonging drugs and the risk of sudden

> > cardiac

> > > > death')

> > > >

> > > > Two of the drugs are used to treat mycoplasmal infections:

> > > > Etrythromycin is prescribed to treat M. pneumoniae and M.

> > penetrans.

> > > > Clarithromycin is prescribed to treat M. pneumoniae, M.

penetrans

> > > and

> > > > M. purim.

> > > >

> > > > RISK LIST:

> > > > 1. Erythromycin (Brand names: E-Base; E-Mycin; E.E.S.;

> > > > Ery-Tab; ERYC; EryPed; Erythrocin; Ilosone)

> > > > 2. Clarithromycin (Brand name: Biaxin)

> > > > 3. Cisapride (Brand names: Propulsid, Prepulsid)

> > > > 4. Domperidone (Brand names: Motilium®)

> > > > 5. Chlorpromazine (Brand name: Largactil, Thorazine)

> > > > 6. Haloperidol (Brand names: Haldol, Haldol Decanoate,

> > > > Apo-Haloperidol, Haldol, Haldol LA, Novo-Peridol,

> > > > Peridol, PMS Haloperidol)

> > > > 7. Pimozide (Brand name: Orap)

> > > >

> > > >

> > > > Dudley & Leslee Dudley © 2005 .

> > > >

> > > > * * * * * * * * * * * * * * * * * * * * * * * * * * *

> > > >

> > > > Antibiotics linked to sudden deaths

> > > > Daily Mail - UK, UK - May 11, 2005

> > > >

> > >

> >

http://www.dailymail.co.uk/pages/live/articles/health/healthmain.html

?

> > > > in_article_id=348255 & in_page_id=1774

> > > >

> > > > A range of commonly prescribed drugs including antibiotics

may be

> > > > responsible for around 15,000 sudden deaths each year in

Europe

> > and

> > > > the United States, researchers claim.

> > > >

> > > > The drugs interfere with electrical activity controlling the

> > > > heartbeat. A study in the Netherlands found they were

associated

> > > with

> > > > a three-fold increased risk of sudden death due to cardiac

arrest.

> > > >

> > > > Two of the drugs are the antibiotics erythromycin and

> > > > clarithromycin. Others on the risk list are cisapride

domperidone

> > > > used to treat gastro-intestinal conditions, and the anti-

psychotic

> > > > medications chlorpromazine, haloperidol and pimozide.

> > > >

> > > > All prolong the heart's QTc interval - a measurement of the

> > > > electrical activity linked to the contraction of heart

muscle

> > cells.

> > > > Drugs that increase the QTc interval can cause life-

threatening

> > > > disruptions of heart rhythms.

> > > >

> > > > Widespread research

> > > > The findings emerged from a study of 775 cases of sudden

heart

> > > death.

> > > >

> > > > Researchers found that the seven drugs were probably

responsible

> > for

> > > > 320 of these deaths.

> > > >

> > > > This equated to about 15,000 deaths per year across Europe

and the

> > > > United States.

> > > >

> > > > But the study's senior author, Dr Bruno Stricker, from the

Erasmus

> > > > Medical Centre in Rotterdam, said that although the

findings were

> > > > significant, it was important to keep them in proportion.

> > > >

> > > > It was normal to expect one or two sudden cardiac deaths per

> > > thousand

> > > > of the population each year in Western countries.

> > > >

> > > > The risk for people taking the drugs rose to around three

per

> > > > thousand.

> > > >

> > > > Vital treatments

> > > > " These drugs are vital treatments for serious conditions in

many

> > > > cases, so it is essential that patients should not stop

taking

> > them

> > > > on their own initiative, " said Dr Stricker, who is also a

senior

> > > > medical officer at the Inspectorate for Healthcare in The

Hague.

> > > >

> > > > " If they are concerned they should talk to their doctor. "

> > > >

> > > > The drugs have all previously been implicated in abnormal

heart

> > > > rhythms (arrhythmia). But the new study is thought to be the

> > first

> > > to

> > > > investigate links with sudden death.

> > > >

> > > > The findings appeared in the European Heart Journal.

> > > > 2005 Associated Newspapers Ltd · Terms & Conditions ·

> > > >

> > > > * * * * * * * * * * * * * * * * * * * * * * * * * * *

> > > >

> > > > Non-cardiac QTc-prolonging drugs and the risk of sudden

cardiac

> > > death

> > > >

http://eurheartj.oupjournals.org/cgi/content/abstract/ehi312v1

> > > > European Heart Journal Advance Access published online on

May 11,

> > > > 2005. European Heart Journal, doi:10.1093/eurheartj/ehi312

> > > > European Heart Journal © The European Society of Cardiology

2005;

> > > All

> > > > rights reserved. Received February 6, 2005, Revised April

1, 2005,

> > > > Accepted April 7, 2005

> > > > Sabine M.J.M. Straus 1, Miriam C.J.M. Sturkenboom 2, Gysèle

S.

> > > > Bleumink 3, Jeanne P. Dieleman 2, Johan van der Lei 4,

Pieter A.

> > de

> > > > Graeff 5, Jan Herre Kingma 6, and Bruno H.Ch. Stricker 7*

> > > > 1 Pharmaco-Epidemiology Unit, Departments of Epidemiology

and

> > > > Biostatistics and Internal Medicine, Erasmus Medical

Center, PO

> > Box

> > > > 1738, 3000 DR Rotterdam, The Netherlands; Department of

Medical

> > > > Informatics, Erasmus Medical Center, 3000 DR Rotterdam, The

> > > > Netherlands; Medicines Evaluation Board, The Hague, The

> > Netherlands

> > > > 2 Pharmaco-Epidemiology Unit, Departments of Epidemiology

and

> > > > Biostatistics and Internal Medicine, Erasmus Medical

Center, PO

> > Box

> > > > 1738, 3000 DR Rotterdam, The Netherlands; Department of

Medical

> > > > Informatics, Erasmus Medical Center, 3000 DR Rotterdam, The

> > > > Netherlands

> > > > 3 Pharmaco-Epidemiology Unit, Departments of Epidemiology

and

> > > > Biostatistics and Internal Medicine, Erasmus Medical

Center, PO

> > Box

> > > > 1738, 3000 DR Rotterdam, The Netherlands; Inspectorate for

Health

> > > > Care, The Hague, The Netherlands

> > > > 4 Department of Medical Informatics, Erasmus Medical

Center, 3000

> > DR

> > > > Rotterdam, The Netherlands

> > > > 5 Medicines Evaluation Board, The Hague, The Netherlands;

> > Department

> > > > of Clinical Pharmacology, University of Groningen,

Groningen, The

> > > > Netherlands

> > > > 6 Inspectorate for Health Care, The Hague, The Netherlands;

> > > > Department of Clinical Pharmacology, University of

Groningen,

> > > > Groningen, The Netherlands

> > > > 7 Pharmaco-Epidemiology Unit, Departments of Epidemiology

and

> > > > Biostatistics and Internal Medicine, Erasmus Medical

Center, PO

> > Box

> > > > 1738, 3000 DR Rotterdam, The Netherlands; Inspectorate for

Health

> > > > Care, The Hague, The Netherlands

> > > > * To whom correspondence should be addressed.

> > > > Bruno H.Ch. Stricker, E-mail: b.stricker@

> > > >

> > > > ABSTRACT

> > > >

> > > > Aims: To assess the association between the use of non-

cardiac

> > QTc-

> > > > prolonging drugs and the risk of sudden cardiac death.

> > > >

> > > > Methods and results: A population-based case-control study

was

> > > > performed in the Integrated Primary Care Information (IPCI)

> > project,

> > > > a longitudinal observational database with complete medical

> > records

> > > > from more than 500 000 persons. All deaths between 1

January 1995

> > > and

> > > > 1 September 2003 were reviewed. Sudden cardiac death was

> > classified

> > > > based on the time between onset of cardiovascular symptoms

and

> > > death.

> > > > For each case, up to 10 random controls were matched for

age,

> > > gender,

> > > > date of sudden death, and general practice. The exposure of

> > interest

> > > > was the use of non-cardiac QTc-prolonging drugs. Exposure

at the

> > > > index date was categorized into three mutually exclusive

groups of

> > > > current use, past use, and non-use. The study population

comprised

> > > > 775 cases of sudden cardiac death and 6297 matched controls.

> > Current

> > > > use of any non-cardiac QTc-prolonging drug was associated

with a

> > > > significantly increased risk of sudden cardiac death

(adjusted OR:

> > > > 2.7; 95% CI: 1.6-4.7). The risk of death was highest in

women and

> > in

> > > > recent starters.

> > > >

> > > > Conclusion: The use of non-cardiac QTc-prolonging drugs in a

> > > > general population is associated with an increased risk of

sudden

> > > > cardiac death.

> > > >

> > > > antibiotic warning:erythromycin & clarithromycin linked to

sudden

> > > > deaths-study

> > > >

> > > > * * * * * * * * * * * * * * * * * * * * * * * * * * *

> > > > FREE BROCHURE: " How to Get an Accurate Polymerase Chain

Reaction

> > > (PRC)

> > > > Blood Test for Mycoplasmal and Other Infections-with a List

of

> > > > International Laboratories " © by and Leslee Dudley

> > > > is sent automatically and immediately to all new

subscribers. It

> > is

> > > > updated with current information and the new version is

posted to

> > > the

> > > > Mycoplasma Registry Reports & News list each month.

> > > > MycoplasmaRegistry-subscribe

> > > >

> > > > FAIR USE: In accordance with Title 17 U.S.C. Section 107,

this

> > > > material is distributed without profit to those who have

> > expressed a

> > > > prior interest in receiving the included information for

research

> > > and

> > > > educational purposes. The Mycoplasma Registry has no

affiliation

> > > with

> > > > the originator of this article nor is the Mycoplasma

Registry

> > > > endorsed or sponsored by the originator. If you wish to use

> > > > copyrighted material from this site for purposes of your

own that

> > go

> > > > beyond 'fair use', you must obtain permission from the

copyright

> > > > owner.

> > > > * * * * * * * * * * * * * * * * * * * * * * * * * * *

> >

> >

> >

> >

[Guest guest]

When I had my first severe herx and ended up in the ER they found my

potassium was low. Then I had to see a cardiologist because they

found the VTach in a sleep study. He said of all the supplements I

take, NEVER miss the potassium. One 99 mg a day should do it. Drink

plenty of fluids he said and he said NOT just water. Plain water or

even worse distilled water can deplete you of minerals that we are

already usually low in.

> > > > > will azithromycin also cause sudden death since its in

the

> same

> > > > > class of antibiotics as the two drugs:

> > > > > 1. Erythromycin (Brand names: E-Base; E-Mycin; E.E.S.;

> > > > > Ery-Tab; ERYC; EryPed; Erythrocin; Ilosone)

> > > > > 2. Clarithromycin (Brand name: Biaxin)

> > > > >

> > > > > Anyone have any info?

> > > > > ------------------------

> > > > >

> > > > > From: " Mycoplasma Registry GWI & CFS " <mycoreg@j...>

> > > > > Date: Fri May 13, 2005  6:40 pm

> > > > > Subject: Mycoplasma Registry Reports-antibiotic

> > > > warning:erythromycin

> > > > > & clarithromycin

> > > > >

> > > > > * * * * * * * * * * * * * * * * * * * * * * * * * * *

> > > > > MYCOPLASMA REGISTRY REPORTS

> > > > > for gulf war syndrome & chronic fatigue syndrome

> > > > > © Dudley & Leslee Dudley 2005. All rights reserved.

> > > > > MycoplasmaRegistry/ MycoReg@

> > > > > * * * * * * * * * * * * * * * * * * * * * * * * * * *

> > > > >

> > > > > Seven drugs interfere with electrical activity

controlling

> the

> > > > > heartbeat and may increase risk of sudden cardiac death.

> (see

> > > > > article and abstract below: 'Antibiotics linked to sudden

> deaths'

> > > > > and 'Non-cardiac QTc-prolonging drugs and the risk of

sudden

> > > cardiac

> > > > > death')

> > > > >

> > > > > Two of the drugs are used to treat mycoplasmal infections:

> > > > > Etrythromycin is prescribed to treat M. pneumoniae and M.

> > > penetrans.

> > > > > Clarithromycin is prescribed to treat M. pneumoniae, M.

> penetrans

> > > > and

> > > > > M. purim.

> > > > >

> > > > > RISK LIST:

> > > > > 1. Erythromycin (Brand names: E-Base; E-Mycin; E.E.S.;

> > > > > Ery-Tab; ERYC; EryPed; Erythrocin; Ilosone)

> > > > > 2. Clarithromycin (Brand name: Biaxin)

> > > > > 3. Cisapride (Brand names: Propulsid, Prepulsid)

> > > > > 4. Domperidone (Brand names: Motilium®)

> > > > > 5. Chlorpromazine (Brand name: Largactil, Thorazine)

> > > > > 6. Haloperidol (Brand names: Haldol, Haldol Decanoate,

> > > > > Apo-Haloperidol, Haldol, Haldol LA, Novo-Peridol,

> > > > > Peridol, PMS Haloperidol)

> > > > > 7. Pimozide (Brand name: Orap)

> > > > >

> > > > >

> > > > > Dudley & Leslee Dudley © 2005 .

> > > > >

> > > > > * * * * * * * * * * * * * * * * * * * * * * * * * * *

> > > > >

> > > > > Antibiotics linked to sudden deaths

> > > > > Daily Mail - UK, UK - May 11, 2005

> > > > >

> > > >

> > >

>

http://www.dailymail.co.uk/pages/live/articles/health/healthmain.html

> ?

> > > > > in_article_id=348255 & in_page_id=1774

> > > > >

> > > > > A range of commonly prescribed drugs including

antibiotics

> may be

> > > > > responsible for around 15,000 sudden deaths each year in

> Europe

> > > and

> > > > > the United States, researchers claim.

> > > > >

> > > > > The drugs interfere with electrical activity controlling

the

> > > > > heartbeat. A study in the Netherlands found they were

> associated

> > > > with

> > > > > a three-fold increased risk of sudden death due to

cardiac

> arrest.

> > > > >

> > > > > Two of the drugs are the antibiotics erythromycin and

> > > > > clarithromycin. Others on the risk list are cisapride

> domperidone

> > > > > used to treat gastro-intestinal conditions, and the anti-

> psychotic

> > > > > medications chlorpromazine, haloperidol and pimozide.

> > > > >

> > > > > All prolong the heart's QTc interval - a measurement of

the

> > > > > electrical activity linked to the contraction of heart

> muscle

> > > cells.

> > > > > Drugs that increase the QTc interval can cause life-

> threatening

> > > > > disruptions of heart rhythms.

> > > > >

> > > > > Widespread research

> > > > > The findings emerged from a study of 775 cases of sudden

> heart

> > > > death.

> > > > >

> > > > > Researchers found that the seven drugs were probably

> responsible

> > > for

> > > > > 320 of these deaths.

> > > > >

> > > > > This equated to about 15,000 deaths per year across

Europe

> and the

> > > > > United States.

> > > > >

> > > > > But the study's senior author, Dr Bruno Stricker, from

the

> Erasmus

> > > > > Medical Centre in Rotterdam, said that although the

> findings were

> > > > > significant, it was important to keep them in proportion.

> > > > >

> > > > > It was normal to expect one or two sudden cardiac deaths

per

> > > > thousand

> > > > > of the population each year in Western countries.

> > > > >

> > > > > The risk for people taking the drugs rose to around three

> per

> > > > > thousand.

> > > > >

> > > > > Vital treatments

> > > > > " These drugs are vital treatments for serious conditions

in

> many

> > > > > cases, so it is essential that patients should not stop

> taking

> > > them

> > > > > on their own initiative, " said Dr Stricker, who is also a

> senior

> > > > > medical officer at the Inspectorate for Healthcare in The

> Hague.

> > > > >

> > > > > " If they are concerned they should talk to their doctor. "

> > > > >

> > > > > The drugs have all previously been implicated in abnormal

> heart

> > > > > rhythms (arrhythmia). But the new study is thought to be

the

> > > first

> > > > to

> > > > > investigate links with sudden death.

> > > > >

> > > > > The findings appeared in the European Heart Journal.

> > > > > 2005 Associated Newspapers Ltd · Terms & Conditions ·

> > > > >

> > > > > * * * * * * * * * * * * * * * * * * * * * * * * * * *

> > > > >

> > > > > Non-cardiac QTc-prolonging drugs and the risk of sudden

> cardiac

> > > > death

> > > > >

> http://eurheartj.oupjournals.org/cgi/content/abstract/ehi312v1

> > > > > European Heart Journal Advance Access published online on

> May 11,

> > > > > 2005. European Heart Journal, doi:10.1093/eurheartj/ehi312

> > > > > European Heart Journal © The European Society of

Cardiology

> 2005;

> > > > All

> > > > > rights reserved. Received February 6, 2005, Revised April

> 1, 2005,

> > > > > Accepted April 7, 2005

> > > > > Sabine M.J.M. Straus 1, Miriam C.J.M. Sturkenboom 2,

Gysèle

> S.

> > > > > Bleumink 3, Jeanne P. Dieleman 2, Johan van der Lei 4,

> Pieter A.

> > > de

> > > > > Graeff 5, Jan Herre Kingma 6, and Bruno H.Ch. Stricker 7*

> > > > > 1 Pharmaco-Epidemiology Unit, Departments of Epidemiology

> and

> > > > > Biostatistics and Internal Medicine, Erasmus Medical

> Center, PO

> > > Box

> > > > > 1738, 3000 DR Rotterdam, The Netherlands; Department of

> Medical

> > > > > Informatics, Erasmus Medical Center, 3000 DR Rotterdam,

The

> > > > > Netherlands; Medicines Evaluation Board, The Hague, The

> > > Netherlands

> > > > > 2 Pharmaco-Epidemiology Unit, Departments of Epidemiology

> and

> > > > > Biostatistics and Internal Medicine, Erasmus Medical

> Center, PO

> > > Box

> > > > > 1738, 3000 DR Rotterdam, The Netherlands; Department of

> Medical

> > > > > Informatics, Erasmus Medical Center, 3000 DR Rotterdam,

The

> > > > > Netherlands

> > > > > 3 Pharmaco-Epidemiology Unit, Departments of Epidemiology

> and

> > > > > Biostatistics and Internal Medicine, Erasmus Medical

> Center, PO

> > > Box

> > > > > 1738, 3000 DR Rotterdam, The Netherlands; Inspectorate

for

> Health

> > > > > Care, The Hague, The Netherlands

> > > > > 4 Department of Medical Informatics, Erasmus Medical

> Center, 3000

> > > DR

> > > > > Rotterdam, The Netherlands

> > > > > 5 Medicines Evaluation Board, The Hague, The Netherlands;

> > > Department

> > > > > of Clinical Pharmacology, University of Groningen,

> Groningen, The

> > > > > Netherlands

> > > > > 6 Inspectorate for Health Care, The Hague, The

Netherlands;

> > > > > Department of Clinical Pharmacology, University of

> Groningen,

> > > > > Groningen, The Netherlands

> > > > > 7 Pharmaco-Epidemiology Unit, Departments of Epidemiology

> and

> > > > > Biostatistics and Internal Medicine, Erasmus Medical

> Center, PO

> > > Box

> > > > > 1738, 3000 DR Rotterdam, The Netherlands; Inspectorate

for

> Health

> > > > > Care, The Hague, The Netherlands

> > > > > * To whom correspondence should be addressed.

> > > > > Bruno H.Ch. Stricker, E-mail: b.stricker@

> > > > >

> > > > > ABSTRACT

> > > > >

> > > > > Aims: To assess the association between the use of non-

> cardiac

> > > QTc-

> > > > > prolonging drugs and the risk of sudden cardiac death.

> > > > >

> > > > > Methods and results: A population-based case-control

study

> was

> > > > > performed in the Integrated Primary Care Information

(IPCI)

> > > project,

> > > > > a longitudinal observational database with complete

medical

> > > records

> > > > > from more than 500 000 persons. All deaths between 1

> January 1995

> > > > and

> > > > > 1 September 2003 were reviewed. Sudden cardiac death was

> > > classified

> > > > > based on the time between onset of cardiovascular

symptoms

> and

> > > > death.

> > > > > For each case, up to 10 random controls were matched for

> age,

> > > > gender,

> > > > > date of sudden death, and general practice. The exposure

of

> > > interest

> > > > > was the use of non-cardiac QTc-prolonging drugs. Exposure

> at the

> > > > > index date was categorized into three mutually exclusive

> groups of

> > > > > current use, past use, and non-use. The study population

> comprised

> > > > > 775 cases of sudden cardiac death and 6297 matched

controls.

> > > Current

> > > > > use of any non-cardiac QTc-prolonging drug was associated

> with a

> > > > > significantly increased risk of sudden cardiac death

> (adjusted OR:

> > > > > 2.7; 95% CI: 1.6-4.7). The risk of death was highest in

> women and

> > > in

> > > > > recent starters.

> > > > >

> > > > > Conclusion: The use of non-cardiac QTc-prolonging drugs

in a

> > > > > general population is associated with an increased risk

of

> sudden

> > > > > cardiac death.

> > > > >

> > > > > antibiotic warning:erythromycin & clarithromycin linked

to

> sudden

> > > > > deaths-study

> > > > >

> > > > > * * * * * * * * * * * * * * * * * * * * * * * * * * *

> > > > > FREE BROCHURE: " How to Get an Accurate Polymerase Chain

> Reaction

> > > > (PRC)

> > > > > Blood Test for Mycoplasmal and Other Infections-with a

List

> of

> > > > > International Laboratories " © by and Leslee Dudley

> > > > > is sent automatically and immediately to all new

> subscribers. It

> > > is

> > > > > updated with current information and the new version is

> posted to

> > > > the

> > > > > Mycoplasma Registry Reports & News list each month.

> > > > > MycoplasmaRegistry-subscribe

> > > > >

> > > > > FAIR USE: In accordance with Title 17 U.S.C. Section 107,

> this

> > > > > material is distributed without profit to those who have

> > > expressed a

> > > > > prior interest in receiving the included information for

> research

> > > > and

> > > > > educational purposes. The Mycoplasma Registry has no

> affiliation

> > > > with

> > > > > the originator of this article nor is the Mycoplasma

> Registry

> > > > > endorsed or sponsored by the originator. If you wish to

use

> > > > > copyrighted material from this site for purposes of your

> own that

> > > go

> > > > > beyond 'fair use', you must obtain permission from the

> copyright

> > > > > owner.

> > > > > * * * * * * * * * * * * * * * * * * * * * * * * * * *

> > >

> > >

> > >

> > >